Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/120184
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSchwarz, Rebecca Lia-
dc.contributor.authorHofmann, Britt-
dc.contributor.authorGergs, Ulrich-
dc.contributor.authorNeumann, Joachim-
dc.date.accessioned2025-08-04T06:33:15Z-
dc.date.available2025-08-04T06:33:15Z-
dc.date.issued2025-
dc.identifier.urihttps://opendata.uni-halle.de//handle/1981185920/122143-
dc.identifier.urihttp://dx.doi.org/10.25673/120184-
dc.description.abstractN6-(R)-Phenylisopropyladenosine (R-PIA), an agonist at A1-adenosine receptors, alone exerts negative inotropic effects (NIE) in the human atrium. This NIE is augmented in the presence of cAMP-increasing agonists like phosphodiesterase inhibitors (cilostamide, rolipram) or a direct activator of adenylyl cyclase (forskolin). Cantharidin inhibits protein phosphatases 1 and 2A (PP1, PP2A). We hypothesized that cantharidin would attenuate this NIE of R-PIA in the presence of cilostamide or forskolin. During open heart surgery (patients were suffering from severe coronary heart disease), isolated human atrial preparations (HAP) were obtained. These HAP were mounted in organ baths and electrically stimulated (1 Hz). For comparison, we studied isolated electrically stimulated (1 Hz) left atrial preparations (LA) from wild type mice. We noted that R-PIA exerted negative inotropic effects in LA and HAP in the presence of cilostamide or rolipram and forskolin that were attenuated by cantharidin. We hypothesize that R-PIA in the presence of phosphodiesterase inhibitors or forskolin stimulates PP in the human atrium. Hence, R-PIA acts, at least in part, by stimulating PP in HAP.eng
dc.language.isoeng-
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/-
dc.subject.ddc610-
dc.titleInhibition of protein phosphatases attenuates A1-adenosine receptor-stimulation induced negative inotropic effects of cAMP-increasing agents in the isolated human atriumeng
dc.typeArticle-
local.versionTypepublishedVersion-
local.bibliographicCitation.journaltitleNaunyn-Schmiedeberg's archives of pharmacology-
local.bibliographicCitation.volume398-
local.bibliographicCitation.pagestart9125-
local.bibliographicCitation.pageend9138-
local.bibliographicCitation.publishernameSpringer-
local.bibliographicCitation.publisherplaceBerlin-
local.bibliographicCitation.doi10.1007/s00210-025-03854-0-
local.openaccesstrue-
dc.identifier.ppn1919699104-
cbs.publication.displayform2025-
local.bibliographicCitation.year2025-
cbs.sru.importDate2025-08-04T06:32:16Z-
local.bibliographicCitationEnthalten in Naunyn-Schmiedeberg's archives of pharmacology - Berlin : Springer, 1873-
local.accessrights.dnbfree-
Appears in Collections:Open Access Publikationen der MLU

Files in This Item:
File Description SizeFormat 
s00210-025-03854-0.pdf1.22 MBAdobe PDFThumbnail
View/Open